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Selective antagonism of cJun for cancer
therapy
Andrew Brennan1, James T. Leech2, Neil M. Kad2 and Jody M. Mason1*
Abstract
The activator protein-1 (AP-1) family of transcription factors modulate a diverse range of cellular signalling pathways
into outputs which can be oncogenic or anti-oncogenic. The transcription of relevant genes is controlled by the
cellular context, and in particular by the dimeric composition of AP-1. Here, we describe the evidence linking cJun
in particular to a range of cancers. This includes correlative studies of protein levels in patient tumour samples and
mechanistic understanding of the role of cJun in cancer cell models. This develops an understanding of cJun as a
focal point of cancer-altered signalling which has the potential for therapeutic antagonism. Significant work has
produced a range of small molecules and peptides which have been summarised here and categorised according
to the binding surface they target within the cJun-DNA complex. We highlight the importance of selectively
targeting a single AP-1 family member to antagonise known oncogenic function and avoid antagonism of anti-
oncogenic function.
Keywords: c-Jun, Activator Protein-1, transcriptional regulator, basic leucine zipper, cancer, peptides, protein-protein
interaction
Background
Activator protein-1 (AP-1) designates a family of onco-
genic transcription factors (TFs) that are integral com-
ponents located at the end of a number of key signalling
networks, controlling vital cellular processes such as dif-
ferentiation, migration, proliferation and apoptosis [1–
6]. AP-1 functions as homo- or hetero-dimeric combina-
tions of proteins in the Fos and Jun sub-families (a
broader definition of AP-1 includes ATF and MAF sub-
families) [7, 8]. As a dimer, AP-1 binds to cognate DNA
sites within gene promotor elements to influence the ex-
pression of a range of target genes that include cyclin
D1, FasL, SDF1, TNFα, proliferin and CD44 [9–11]. This
review will focus on cJun, an AP-1 family member which
is found to be upregulated or overexpressed in a large
number of cancers (for a list of cancers associated with
specific AP-1 members, see Table 1) [47–50]. cJun has
since become a major focus for drug discovery, and its
terminal activity within a number of pathways makes for
a compelling target to ablate oncogenic signals that
occur at any signalling level. This review will describe
the role of AP-1 in general and how cJun specifically is
dysregulated in various cancers. We describe antagonists
from the literature, categorised according to the inter-
action surface within the cJun-DNA complex they target,
as potential therapeutics against cJun dysregulation.
AP-1 Structure and Function
AP-1 proteins bind to DNA via their basic leucine-
zipper (bZIP) domain (Fig 1a); comprised of an N-
terminal DNA binding domain (DBD) and C-terminal
leucine zipper (LZ). The LZ is the site of AP-1 dimerisa-
tion where an intermolecular interaction is facilitated by
the formation of an α-helical coiled coil. This incorpo-
rates hydrophobic packing of i, i+7 repeating aliphatic
hydrophobic residues (a position of the heptad repeat),
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Table 1 Examples of specific cancer types linked to dysregulated activity of AP-1 family members. In brackets we have indicated
whether evidence points to up- or down-regulation of the AP-1 family member
AP-1 family member Type of cancer Up/down-regulation References
cJun Breast cancer Upregulation [12, 13]
Colorectal cancer Upregulation [14]
Fibrosarcoma Upregulation [15]
Glioma Upregulation [16]
Hodgkin lymphoma Upregulation [17]
Lung cancer Upregulation [18]
Myeloid leukaemia Upregulation [19]
Urothelial carcinoma of the bladder Upregulation [20]
JunB Breast cancer Upregulation [21]
Cervical cancer Upregulation [22]
Colon cancer Upregulation [23]
Fibrosarcoma Upregulation [15]
Head and neck squamous cell carcinoma Upregulation [24]
Hodgkin lymphoma Upregulation [17]
Prostate cancer Downregulation [25]
JunD Cervical cancer Upregulation [22]
Prostate cancer Upregulation [26, 27]
cFos Breast cancer Upregulation [28]
Cervical cancer Upregulation [22]
Colon cancer Upregulation [23]
Gastric cancer Downregulation [29]
Head and neck squamous cell carcinoma Upregulation [30]
Ovarian cancer Downregulation [31]
Pancreatic cancer Upregulation [32]
Skin cancer Upregulation [33]
Tongue cancer Upregulation [34]
Urothelial carcinoma of the bladder Upregulation [20]
FosB Breast cancer Downregulation [35]
Colon cancer Downregulation [23]
Gastric cancer Downregulation [36]
Non-small cell lung cancer Downregulation [37]
Ovarian cancer Upregulation [38]
Pancreatic cancer Downregulation [39]
Fra1 Breast cancer Upregulation [40]
Cervical cancer Downregulation [22]
Colon cancer Upregulation [41]
Liver cancer Upregulation [42]
Lung cancer Upregulation [43]
Skin and hand and neck squamous cell carcinoma Upregulation [44]
Fra2 Breast cancer Upregulation [45]
Non-small cell lung cancer Upregulation [46]
Tongue cancer Upregulation [34]
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and leucine residues (d position) which are flanked by
polar and charged residues (e and g positions). The
DBD forms an N-terminal extension of the α-helices
from each protein to grip the DNA in a manner compar-
able to forceps. This inserts into the DNA major groove
where basic sidechains interact favourably with the DNA
phosphate groups, while key residues form specific
hydrogen bonding contacts with bases within the recog-
nition sequence [52, 53].
AP-1 proteins bind to a pseudo-palindromic DNA se-
quence (5’-TGA C/G TCA-3’) known as the 12-O-
tetradecanoylphorbol-13-acetate (TPA) response elem-
ent (TRE) [54–56]. The DBD of each AP-1 protein
within a given dimer binds to a separate half site (5’-
TGA-3’) on the sense/antisense strands, separated by a
C/G spacer base. The cFos-cJun heterodimer has shown
binding promiscuity to single nucleotide variants (SNVs)
of the TRE sequence with up to a 40-fold variation in af-
finity [53]. SNVs of the TRE site, present throughout the
human genome, likely provide a layer of modulation to
the ability of AP-1 dimers to alter the transcription of
genes where they occur. AP-1 dimers may also bind to
the cAMP response element (CRE, 5’-TGA CG TCA-3’)
with a relevant though weaker affinity [57]. Crystal
structures of the cJun homodimer interacting with both
TRE and CRE site DNA are available (PDB codes: 1H7H
for TRE, 1JNM for CRE). The binding affinities for these
related DNA sites is controlled by AP-1 dimer compos-
ition, which in some cases leads to changes in binding
site preference (particularly within the broader definition
of AP-1 which includes Jun/Fos-ATF/MAF heterodi-
mers) [58, 59]. In totality, this produces a regulatory sys-
tem where the expression level of individual AP-1
proteins, and their subsequent nuclear transport, control
the amounts of each AP-1 dimer available to bind [60–
62]. The sequence of a potential DNA binding site (TRE,
CRE or SNVs thereof) will then define the affinity for
each dimer present. This allows global alterations in AP-
1 expression, and therefore dimer composition, induced
by signalling events to produce a fine-tuned effect at a
specific site of transcription.
All AP-1 family members have transactivation (TA)
domains but only the Fos sub-family have been shown
to have transrepression (TR) domains; found at their C-
terminus (Fig 1b) [63–67]. Generally, these domains
have been identified by mutation/deletion of residues/re-
gions though little further mechanistic study has been
carried out. The transactivational activities of cJun, cFos
and FosB are considered strong whereas activities for
JunB, JunD, Fra-1 and Fra-2 are considered weak or re-
pressive [50, 68]. This activity will be modulated by both
the bZIP-DNA binding affinity and the activity of the
domains themselves, which have some sequence diver-
sity and therefore presumably differences in activity. As
Fig. 1 Sequence and structure of AP-1 proteins. a Crystal structure of the cFos-cJun heterodimer binding to DNA (PDB code: 1FOS); b Schematic
illustrating the domain structures of AP-1 proteins, adapted from Ref [51]; c Sequence alignment of the bZIP domains from selected AP-1 proteins
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with DNA site specificity, the transactivation activity is
modulated by AP-1 dimer composition.
AP-1 Activity
The activity of AP-1 is controlled by the cellular context
within which it is operating. This cellular context can be
thought of in terms of AP-1 protein expression levels
defining the prominent dimer compositions; the post
translational modification of AP-1 proteins which can
enhance or diminish activity; and the genetic organisa-
tion within a given cell as defined by epigenetics. The
importance of cellular context is highlighted by the pro-
apoptotic activity of cJun in neurons, in contrast with the
anti-apoptotic activity of cJun in hepatocytes [68]. The
various roles of AP-1 components have been the subject
of significant study using gene knockout (KO) and trans-
genic mice, as discussed thoroughly in a review by Wol-
fram et al [50]. They describe the embryonic lethality of
cJun, JunB and Fra-1 (showing they are indispensable) but
KO of any AP-1 causes some detrimental effect such as
osteopetrosis (cFos KO) or male sterility (JunD KO). AP-1
KO and transgenic mice were phenotypically diverse im-
plying clear differences in the function of these proteins.
In addition to observing the effect of AP-1 family protein
KO, specific genes which are under AP-1 transcriptional
control have been elucidated. AP-1 cellular control is me-
diated through activity on genes including cell-cycle regu-
lators such as cyclin D1, cyclin A, apoptotic proteins such
as FasL and TNF-α, chemokines such as SDF1 and many
others [9–11, 69, 70].
AP-1 proteins respond to numerous environmental
and cellular stimuli including cytokines such as TNFα,
hormones and neurotransmitters such as growth hor-
mone, growth factors such as EGF, bacterial lipopolysac-
charide (LPS), UV damage to DNA and reactive oxygen
species [1–5, 71–78]. Each stimulus produces a signal-
ling cascade which can alter the activity of AP-1 by
changing transcription or by direct activation. The signal
is passed through a mitogen-activated protein kinase
(MAPK) cascade (sometimes initiated by a small G pro-
tein such as RAS or Rac) which terminally acts upon
transcription factors. cJun N-terminal kinase (JNK) and
p38 have both been shown to act in this manner by their
phosphorylation of transcription factors including
myocyte-specific enhancer factor 2C (MEF2C), activating
transcription factor 2 (ATF2) and cJun [79, 80]. It is
known that MEF2C, ATF2 and cJun itself are able to in-
fluence cJun expression [81–84]. JNK increases cJun
transactivation activity through phosphorylation of Ser63
and Ser73 within the TA domain [79]. JNK phosphoryl-
ation has also been shown to decrease ubiquitination-
dependent proteasomal degradation of cJun which ef-
fectively increases cJun activity by virtue of increased
cJun levels [85]. The array of interconnected
components within the AP-1 signalling system allows
the transduction of multiple pathways; balancing signals
to define transcription and allow AP-1 to assert its role
in cellular processes. Some cJun pathways that generalise
aspects of AP-1 signalling are shown in Fig 2.
AP-1 as an Oncoprotein
Although AP-1 dysfunction has been implicated in other
pathological conditions including asthma and rheuma-
toid arthritis, cancer is the most prominently studied
and is the focus here [47–51, 86, 87]. Some hallmarks of
cancerous cells which can be linked with AP-1 dysfunc-
tion are growth signal autonomy, angiogenesis, lack of
apoptosis and uncontrolled cell migration. The func-
tional role of AP-1 proteins has been shown to vary,
resulting in a mixture of oncogenic and anti-oncogenic
effects, depending upon cellular context and dimer com-
position [48]. For example, a cJun homodimer tends to
have oncogenic activity however a cJun-JunB heterodi-
mer can repress that function [88]. We may look to the
specific case of breast cancer where cJun has been
shown to be upregulated whereas FosB is downregulated
[12, 13, 35]. In this context, therefore, AP-1 family mem-
bers must be considered and treated individually. We
focus on the role of cJun which has generally been
shown to have an oncogenic effect. Early studies on the
role of cJun in cancer showed sequence homology with
known viral oncoprotein vJun, and overexpression of
cJun was capable of malignantly transforming rat embry-
onic cells towards a cancer phenotype [67, 89, 90]. Al-
though this alone did not imply cJun overexpression as
an in vivo cause of human cancer, it was a strong indica-
tor of the involvement of cJun and led to an intense
period of further research.
Genetic studies can illuminate the target genes through
which cJun exerts influence to produce hallmark cancer
cell behaviours. cJun has been shown to regulate a range
of genes involved in tumour development including cyclin
D1 (upregulated to stimulate proliferation), Fas (downreg-
ulated to inhibit apoptosis), proliferin (upregulated to
stimulate angiogenesis) and CD 44 (upregulated to stimu-
late invasiveness) [48, 91–95]. However, the picture is not
simplistic as cJun may also contribute anticancer effects,
for example it upregulates BCL-2 interacting mediator of
cell death (BIM) which stimulates apoptosis [96]. cJun ap-
pears to be best described as an oncoprotein but there is
balance in its effects; tempered by cellular context.
cJun in Cancer
Evidence for the role of cJun in cancer has been devel-
oped by quantifying the amount of cJun in various pri-
mary cancer tissue samples to create a correlative link.
One such study with lung cancer patients demonstrated
cJun overexpression in 31% of the tumour samples
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tested [18]. The involvement of cJun was illustrated via
immunohistochemistry which could not detect cJun in
normal conducting airway and alveolar epithelial cells, but
it was found in histologically atypical areas. Another ex-
ample of this difference was observed in colorectal adeno-
carcinoma tumour samples, where cJun was found to be
significantly increased yet was undetectable in normal-
appearing colonic mucosa, distant from tumours [14].
One study involving samples from breast cancer pa-
tients was able to show cJun at particularly high levels at
the invasive front of breast cancer tumours compared to
benign breast cells [12]. These high levels of cJun were
linked with proliferation and angiogenesis and a correl-
ation was found between cJun expression during cell
cycle progression and lower survival rate. cJun has also
been shown to be strongly overexpressed in cells
throughout the tumours of Hodgkin lymphoma patients
[17]. A study of acute myeloid leukaemia patient samples
showed cJun expression was raised compared to normal
bone marrow mononuclear cells [19]. Expression levels
were linked to the grade of malignancy in glial tumours,
with the role of cJun in producing malignant tumour
properties (proliferation, migration and invasion) also il-
lustrated in the same study [16].
The role of cJun in cancer has also been probed using
an ex-vivo lung cancer model, which indicated that cJun
was elevated in circulatory tumour cells compared to
primary tumours and metastatic lesions [97]. Overex-
pression of cJun in MCF-7 cells (a breast cancer cell
line) has been shown to induce an invasive cancer
phenotype which is clearly linked to the high levels of
cJun seen in the invasive edge of tumours from patients
[13]. This model system produced a highly relevant fea-
ture observed in the clinic, that of hormone resistance.
Fig. 2 Overview of selected cJun signalling pathways. In general, a stimulus is passed through a MAPK cascade (sometimes via a small G protein)
to alter the activity of transcription factors which act upon the cJun gene; this changes expression of target genes by the formation of an AP-1
dimer which binds to TRE DNA. Exemplary pathways have been shown which are indicative of the general signalling through which a stimulus
leads to cJun mediated cellular changes. The pathways are therefore not necessarily complete as well as some of these activations occurring
indirectly. Created with Biorender.com
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This follows from previous work that showed cJun and
cFos inhibit estrogen receptor transcription in MCF-7
cells [98]. This reduction in estrogen receptor protein
reduces the inhibitory effect of the drug tamoxifen
which functions by binding at these sites. cJun overex-
pression in these cells is therefore a close mimic of the
condition in patients which have been treated with tam-
oxifen but recur with drug-resistant, aggressive tumours.
A further link between cJun/cFos and drug resistance
was observed in human leukaemia cells where a drug re-
sistant line was shown to have higher cJun/cFos levels
than a drug sensitive line [99].
The involvement of cJun in cancer can also be illus-
trated by observing the effect of cJun depletion/KO or
inactivation within cancer cell lines. In one such piece of
work cJun was depleted in Friend murine erythroleukae-
mia cells by the use of sequence specific antisense oligo-
nucleotides [100]. This was shown to halt proliferation
of logarithmically growing cells, pushing them into a
resting phase until cJun was restored. In a nasopharyn-
geal carcinoma cell line, silencing of cJun was shown to
decrease cell migration and invasion [101]. Conditional
KO of cJun, through a floxed allele, produced signifi-
cantly fewer tumours in a chemical-induced liver cancer
model; this was shown to operate in part through a re-
duction in cJun antagonism of the proapoptotic protein
p53 [102]. Expression of a cJun mutant lacking its TA
domain can supress the oncogenic transformation in-
duced by an activated Ras gene in the presence of TPA
[103, 104]. Another cJun TA deletion mutant was shown
to prevent tumour formation in two malignant mouse
epidermal cell lines [105].
Hijacking Cell Signalling
cJun is active in response to a web of signalling path-
ways, whereby the inputs of these various signals are in-
tegrated into the output of transcriptional activity
mediated by cJun binding to TRE (or related) DNA (Fig
2). These signalling pathways are a source of tumori-
genic effect on cJun activity, by the production of in-
creased levels of activated cJun. This can be illustrated
by the KO of cJun N-terminal phosphorylation in a
mouse model of intestinal cancer which reduced tumour
number and size and prolonged lifespan [106]. Typically,
cJun expression levels remain low until a stimulus ele-
vates levels of activated protein [14, 18]. However, in
some cancers these inductive pathways become constitu-
tively activated. For example, this switch to constant ac-
tivation of cJun (alongside other AP-1 family members
and early transcription factors) was shown in human
head and neck squamous cell carcinoma cell lines [107].
Cancer can therefore be thought of as hijacking these
cellular processes, turning them from responsive
pathways to produce conditional activity into permanent
signals for growth and migration.
Pathogen sensing, via Toll-like receptor (TLR) proteins,
is one such pathway hijacked by cancer (Fig 2). The ob-
served link between prostatitis and prostate cancer [108]
has been suggested to occur due to gram-negative bacter-
ial or DNA virus infection in which pathogen LPS bind to
TLR proteins [109]. TLR4 expression has been associated
with poor progression-free survival in prostate cancer
[110], a trend also observed in hepatocellular carcinoma
[111]. Subsequent work used silencing of MKK4 or inhib-
ition of JNK activity to show that Toll receptor signalling
enhanced hepatocellular carcinoma invasiveness [112].
Taken together this links overactivation of the Toll recep-
tor/JNK pathway with constitutive activation of cJun in
cancer. Constitutive activation of JNK has also been
shown in glioma cells [113]. The level of activation was
correlated with the histological grade of the tumour and
EGFR expression. In this case the cancerous cell has
hijacked the cells ability to respond to EGF. This JNK acti-
vation is crucial for the ability of the glioma cells to re-
main “stem-like” by self-renewing, and also plays a role in
drug resistance [114].
cJun activity is mediated by its ability to persist within
cells so alterations in degradation signalling may produce
cancer phenotypes. Serine/threonine kinase receptor-
associated protein has been shown to be overexpressed in
a number of human cancers and is relevant here for its
role in cJun regulation [6, 115]. It has been shown to in-
hibit cJun ubiquitination and therefore proteasomal deg-
radation. This work illustrated how the increased stability
of cJun led to increased cyclin D1 expression and in-
creased proliferation. In melanoma, mutant BRAF or N-
RAS has been shown to upregulate MAPK signalling
[116–118]. It has been shown that the subsequent upregu-
lated activity of ERK produces an increase in cJun tran-
scription and subsequent protein stability [119]. cJun can
also be protected from degradation by bZIP binding part-
ners. This was shown to be the case for Fra-1 where RAS-
induced overexpression of this oncogenic protein was
shown to increase cJun stability [120].
cJun Antagonism
The literature paints a broad picture of cJun dysregula-
tion across a number of cancers and collectively shows
that cJun is generally overactive and as such could be
antagonised for therapeutic effect. Cancer related effects
can be induced at any level of signalling, but as dysregu-
lation is modulated at the transcriptional endpoint of
cJun, antagonism there will ablate any oncogenic signal-
ling in the pathway. Signalling pathways may also modu-
late multiple TFs and other processes, so attempts to
therapeutically interact earlier in the pathway will in-
crease the likelihood of nonspecific effects, which can be
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undesirable. We generally observe these issues when ob-
serving the range of natural products which have been
investigated for chemoprotective or chemotherapeutic
effects related to AP-1 dysregulation, such as resveratrol
and harmal extract [121–123]. They have the potential
to produce beneficial outcomes but their mechanism is
typically poorly defined; usually due to their action on
multiple targets.
Although the focus here is cJun it is important to re-
iterate that some AP-1 components can produce onco-
genic effects, and others are anti-oncogenic depending
on cellular context and specific dimer composition. A
therapeutic would seek to antagonise cJun oncogenic ac-
tivity selectively while avoiding interaction with closely
related AP-1 family members which are functioning nor-
mally or may be producing anti-oncogenic effects. An-
tagonism of cJun can ultimately be achieved by either
preventing the bZIP domain from engaging with the
DNA or by preventing the binding of the TA domain to
any relevant interaction partners. Currently, the most at-
tractive site for cJun antagonism is to directly modulate
DNA binding at the bZIP (either by inhibition of dimer-
isation or by preventing the bZIP from docking to the
DNA), since this has already received significant study,
whereas little is known about binding at the TA domains
of AP-1 proteins. To antagonise complex formation, it is
important to study the binding surfaces which bring the
functional structure together (Fig 3). This consists of an
extended three component interface involving dimerisa-
tion of the LZ domains and the interaction of the DBD
from each monomer with the DNA. In this section we
shall describe a range of cJun antagonists (Table 2),
categorised by the binding interface they target, to
sketch a picture of the field.
Antagonising TRE sites
Drug candidates targeting AP-1 generally and cJun spe-
cifically have historically tended to be small molecules.
The majority have focused on the DNA TRE site since
this presents a small, defined target surface suited to
small molecules. MLN44 (or XR5944) is a sequence spe-
cific DNA intercalator which has been shown to block
cJun binding to DNA containing the TRE site in a dose-
dependent manner [129]. Electrophoretic mobility shift
assay (EMSA) experiments in this study showed that 25
μM of the compound was required to approach 100% in-
hibition. Structural NMR studies were used to show how
the drug interaction with the DNA major groove pre-
cludes cJun DBD insertion. MLN44 was also shown to
inhibit transcription and ex vivo studies indicated effi-
cacy in a range of cancer tissues [130, 131]. However, an
issue of selectivity is common among small molecule
DNA binders. As with the TFs they are designed to in-
hibit, the specificity described for them remains relative,
with off target binding possible at related DNA se-
quences and even non-related sequences. MLN44, for
example, has also been shown to bind to the estrogen re-
sponse element; raising the question of off-target effects
[132, 133]. Clinical trials for this molecule appear to
have stalled at an early stage.
Retinoids are a vitamin A-related class of molecules,
some of which have been shown to bind to TRE DNA
sites and are being investigated for their anticancer ef-
fects [134]. One TRE-specific retinoid, SR11302, has
Fig. 3 Schematic of cJun binding interfaces and molecules that target them. The cJun-DNA interaction can be antagonised by binding to the
TRE site on DNA (MLN44 [129], SR11302 [135]), the cJun DBD (T-5224) [51], the cJun LZ (anti-Jun and anti-Fos SZ [144], FosUisCan [125]) or the full
cJun bZIP domain (A-Fos [148])
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been investigated in an ex vivo lung cancer model and
was shown to reduce formation of metastatic lesions
[135]. Retinoids unsurprisingly bind to the retinoic acid
response element (RARE) in addition to the TRE. It has
been shown that the purported antitumour effect of
these molecules is mediated by TRE binding and not
RARE binding [136]. However, RARE binding does
occur and although off target effects like these may not
be inherently detrimental, they should be minimised.
Veratramine is an alkaloid, derived from Veratrum
plants, which has also been identified as a selective TRE
site binder which can regulate AP-1-dependent gene
transcription [137]. This compound at 20 μM was
shown to reduce approximately 90% of transactivation
activity in a luciferase reporter assay. Further research is
required into the selectivity and potential efficacy of this
molecule as a cancer therapeutic.
One interesting piece of work went beyond the use of
small molecules and incorporated a peptide conjugate.
This saw an anthraquinone derivative linked to a small
peptide corresponding to a truncated region of the cJun
DBD [138]. A conserved motif within all AP-1 protein
DBD sequences was utilised that centred around the
Lys-Cys-Arg residues (residues 268-270 in cJun; Fig 1c).
A number of sequences were tested involving five to
seven residues around this motif. This combination of a
high affinity non-specific DNA intercalator with the
lower affinity but TRE-site specific peptide was shown to
displace AP-1 from binding to TRE DNA. The EMSA
experimental set up used in this study showed the best
construct to be active in low μM concentrations; achiev-
ing 74% inhibition at 16.8 μM.
Antagonising the cJun DBD
If the problem of TRE selectivity were resolutely solved,
it is important to note that another selectivity issue
would persist, since these molecules would inhibit bind-
ing of all AP-1 family proteins (and any other relevant
bZIP) to TRE DNA. Some AP-1 proteins that bind TRE
sites may have an anti-oncogenic effect, and it is there-
fore important to block a specific AP-1 dimer, rather
than a whole family to promote the desired outcome.
Whilst binding to the TRE site can provide therapeutic
results, greater selectivity to a single AP-1 component
Table 2 Summary of known antagonists of the cJun-TRE DNA interaction. Included are known mode of binding as well as








100% inhibition in EMSA assay at 25 μM [129–133]
SR11302 TRE DNA Treatment prior to TPA induction of tumours
produced a 67.9% reduction in papillomas per
mouse
[134–136]
Veratramine TRE DNA 90% reduction in transactivation at 20 μM in
luciferase reporter assay






TRE DNA Approaching 100% inhibition in EMSA assay at 1
μM
[138]
T-5224 DBD of AP-
1 proteins
IC50~10 μM [51, 139, 140]
NY2267 cJun LZ 74% reduction in transactivation at 20 μM in
luciferase reporter assay
Designed as c-Myc antagonist so
not selective
[141]
cFos LZ cJun LZ For cFos LZ-cJun LZ: Kd = 26.6 μM (by ITC) [142, 143]
JunB bZIP cJun LZ Eightfold excess of JunB reduced transactivation
tenfold in a luciferase reporter assay
[88]
anti-Jun and anti-Fos SZ cJun LZ 50% of Jun LZ or Fos LZ bound to the antagonist
when the three are mixed in equimolar amounts
[144]
FosW cJun LZ For FosW-cJun LZ: Kd = 39 nM (by ITC) [145, 146]
FosWCANDI cJun LZ For FosWCANDI -cJun LZ: Tm = 52 degrees C(by
CD)
Reduced affinity with no increase
in selectivity compared to FosW
[154]
CPW cJun LZ For CPW-cJun LZ: Kd = 750 nM (by ITC) [147]
FosUisCan cJun LZ For FosUisCAN-cJun LZ Tm of 57 °C (by CD) [125]
A-Fos cJun bZIP For A-Fos-cJun bZIP: Kd = 30 pM (by CD thermal
shift from Tm of 72.1 °C)
[148]
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should provide a higher degree of therapeutic control.
An additional issue from producing antagonists which
bind selectively to the TRE may arise when considering
the ability of cJun to bind to SNVs of TRE or CRE sites
[53, 57]. A potential antagonist may not possess the
same binding promiscuity amongst these related sites as
cJun so there may be relevant transcription sites which
are not being blocked. Conversely, blocking only the
TRE sites may shift the binding equilibria to increase
AP-1 binding at non-TRE sites which could also be
detrimental.
Blocking the DBD-DNA interaction with increased se-
lectivity could therefore be better achieved by targeting
the DBD of cJun rather than the TRE site on the DNA.
One example of a molecule binding to the AP-1 DBD
exists in the literature: T-5224 [51]. This small molecule
is based on a cyclic peptide which was designed to in-
hibit the cJun-cFos dimer binding to DNA [149]. The
cyclic decapeptide Ac-c [Cys-Gly-Gln-Leu-Asp-Leu-Ala-
Asp-Gly-Cys]-NH2 was produced de novo by inspection
of the cJun and cFos target DBDs and then subsequent
experimental optimisation. Computational and NMR
methods indicate that the peptide is bound to both
DBDs and an enzyme-linked DNA−protein interaction
assay indicated an IC50 of 8 μM. T-5224 was computa-
tionally designed based on this peptide, and cellular as-
says in relation to arthritis indicated an IC50 of 10 μM.
T-5224 represents the small molecule inhibitor of AP-1
which has gone the furthest in clinical trials having made
it to a discontinued phase II trial for its effectiveness in
arthritis. It has also been shown to have anticancer activ-
ity in various models [139, 140]. Further clinical study of
this molecule (or the peptide from which it is derived) as
an anticancer agent may prove fruitful in the future.
Antagonising the LZ Interface
Sequence alignment of AP-1 proteins (Fig 1c) indicates a
high degree of similarity in the DBDs, particularly within
the sub-families. This selectivity issue alongside the rela-
tively weak binding affinity of the only known binder to
date implies that targeting the cJun DBD will be highly
challenging. The LZ domain of cJun exhibits more sig-
nificant sequence diversity than the DBD so the focus
may switch there. Targeting the LZ binding interface
raises different challenges which must now be consid-
ered. Due to the large surface area of the LZ, which lacks
defined binding pockets, small molecules may not bind
as effectively. Some small molecules have been devel-
oped which bind to the cJun LZ however they were ini-
tially produced as c-Myc antagonists, indicating an issue
with selectivity [141]. To our knowledge, no specific
small molecule cJun LZ binders have yet been
developed.
To target the LZ binding surface with significant po-
tential for selective binding, work on protein-based an-
tagonists has instead developed; a less commonly
utilised but growing field of study [150, 151]. Peptides
can move beyond the Lipinski rules of small molecule
drugs and utilise a larger binding surface, which can be
particularly useful for protein surfaces without defined
binding pockets suited to small molecules. This can pro-
duce higher affinity binding than possible with small
molecules, which generally operate at lower potency mi-
cromolar affinities. Larger surfaces also provide the po-
tential for more target-specific peptide drugs which can
reduce toxicity. Peptide-based drugs tend to be less im-
munogenic because they are composed of natural com-
ponents that are degraded into safe metabolites (amino
acids), which prevents accumulation in tissues. The sim-
plest approach to producing peptides which bind to the
cJun LZ is to look to the range of known natural bZIP
proteins which bind to cJun. Clearly, the LZ from any
bZIP protein which is known to bind to cJun may oper-
ate as an antagonist. The cFos-cJun LZ domains in isola-
tion have been shown to bind with a Kd of 27 μM by
ITC [142]. The potential for antagonism has been shown
using cFos and cJun LZ peptides in vivo where they
inhibited maturation of Xenopus oocytes through cJun
antagonism [143]. JunB has been shown to bind to the
cJun LZ and reduce transactivation according to a lucif-
erase reporter assay [88].
Using WT protein LZ sequences as a guide, one can
work towards producing an enhanced antagonist
through rational design. LZ design rules to aid in bind-
ing selectivity have been studied in the specific case of
cJun and related bZIP proteins [152, 153]. By consider-
ing the core packing at the a and d heptad positions and
electrostatic interactions at the e and g positions of the
target, selective and high affinity binding of an antagon-
ist can be achieved. Rational optimisation of a WT se-
quence was performed in one case by Bains et al
through modification of the cJun LZ [144]. This ration-
ally designed cJun LZ Ala298Val peptide was referred to
as an anti-Jun and anti-Fos superzipper (SZ). This sim-
ple point mutation at an a heptad position in the cJun
LZ was predicted to produce more extensive van der
Waals interactions with its binding partners. The SZ was
subsequently shown to bind to both the cJun and cFos
LZ peptides, with a small preference for cFos, using ana-
lytical HPLC experiments.
However, maintaining a high level of sequence similar-
ity with native bZIP proteins is likely to present a prob-
lem with selectivity as these proteins are known to
interact with multiple partners. Optimisation of selective
binding to cJun may instead be achieved by the explor-
ation of novel sequence design space. High throughput
library screening approaches are being utilised to test
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large numbers of peptide sequences for cJun LZ binding,
allowing for more randomised design. Using an intracel-
lular protein-fragment complementation assay (PCA), a
~62,000 member library was screened to produce a pep-
tide named FosW [145]. This peptide was shown to bind
to the cJun LZ with a Kd of 39 nM by ITC which illus-
trates the large increase in binding affinity made possible
by targeting this large protein surface [146]. However,
FosW was also shown to bind tightly to itself and to
cFos (and likely most AP-1 family members).
Clearly a selective cJun antagonist must outcompete
the range of possible interactions available in the cellular
context (Fig 4). Both target and antagonist can homodi-
merize and they can also potentially bind to off-target
bZIP proteins, so the cJun-antagonist interaction must
be preferred over all of these options. The setup for
PCA optimises selective target binding over homodimer-
isation but off-targets are not considered. The Competi-
tive And Negative Design Initiative (CANDI) is an
extended version of the PCA assay where off-target pro-
teins are also present; this means selected winner pep-
tides must bind to the target with a greater affinity than
the off-target (and other undesirable interactions). The
utility of the technique was shown by the generation of a
novel peptide that bound specifically to cFos in the
presence of cJun, though the attempt to generate a cJun
targeting peptide (FosWCANDI) did not produce the de-
sired selectivity [154]. Screening of a different peptide li-
brary using CANDI methodology may produce better
results. Another library screening methodology called
CIS display has also been utilised in tandem with PCA
to allow for larger libraries to be screened in vitro before
further in cell optimisation by PCA to produce a peptide
named CPW. This has been shown to bind to the cJun
LZ with a Kd of 750 nM [147]. A wide range of peptide
library screening techniques exists beyond CIS and PCA
but these have not yet been used to screen for cJun
antagonists.
The exploration of novel sequence space for cJun an-
tagonists can be expanded by the use of computational
approaches. There is a prominent research drive to util-
ise the information encoded in bZIP sequences to com-
putationally predict interactions [124–126, 155, 156].
This work involves the production of large experimental
datasets through which predictive computational
methods can be developed. This allows the screening of
significantly larger libraries of peptide sequences with
the caveat that comes with in silico approaches: outputs
are predictions which must be experimentally tested.
Our group used an initial in silico screening of a large
Fig. 4 Overview of the potential interactions of a cJun antagonist. This highlights some potential competitive interactions which the antagonist
must overcome in order to selectively bind to the cJun target; outcompeting both homodimerisation and interactions with off
target components
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library to produce a list of antagonist sequences that are
predictively ranked by target binding and/or selectivity
[125]. This information is then used to produce smaller,
higher quality libraries that are accessible to experimen-
tal approaches. The PCA screen of this refined library
produced FosUisCan, which binds tightly to the cJun LZ.
Although other peptides are known which bind with
higher affinity to the target (such as FosW or CPW), this
peptide is significantly more selective due to the lower
affinity of homodimerisation and affinity for cFos.
Antagonising the Full bZIP Domain
To optimise cJun antagonism, it may be pertinent to
consider how the components of the target complex
exist in equilibrium within cells. The binding of cJun to
DNA can potentially occur via two mechanisms. A cJun
monomer either binds to the DNA followed by dimerisa-
tion with another bZIP or cJun finds a bZIP partner be-
fore binding to the DNA as a preformed dimer. Multiple
lines of inquiry have indicated that the former is gener-
ally preferential for bZIP domains, though the latter also
occurs [127, 128, 157]. In the case of the related GCN4
protein, from yeast, the two mechanisms of DNA bind-
ing appear to occur at the same rate [158]. It is therefore
important to consider both a cJun monomer bound to
DNA and a free cJun monomer as our targets for a po-
tential therapeutic.
This raises a potential problem with the antagonists
previously discussed; in terms of their functional activity.
Whilst an antagonist is bound to the DBD of cJun or the
TRE site, dimerisation of cJun may still occur which pre-
pares the protein for DNA binding whenever these an-
tagonists disassociate. Alternatively, an antagonist may
be bound to the LZ of cJun whilst the DBD is searching
the DNA for a TRE site, ready to form a dimer and in-
fluence transcription upon LZ antagonist dissociation.
As monomer binding to the DNA is the energetically
preferred initiation step, blocking this DBD-DNA inter-
action is the priority. However, binding to the full bZIP
domain inhibits either possible initiation step, and may
therefore be considered the preferred route for antagon-
ism. Binding to the full cJun bZIP domain may also
allow higher affinity antagonists to be developed due to
the larger binding surface available.
The Vinson group has developed a methodology which
utilises known LZ antagonists and appends an extension
capable of binding to the target DBD [148, 159]. Initially,
they rationally designed an acidic extension to bind to
the DBD of C/EBP-alpha which they appended to a pep-
tide which binds to the LZ. The rational design involved
the incorporation of negatively charged Glu residues to
promote intramolecular electrostatic interactions with
Arg/Lys sidechains in the DBD. Secondly, the LZ heptad
pattern of Leu at the d positions was extended into this
acidic region in an attempt to extend the LZ packing
into the DBD. This rational design was then modified
slightly to target the cJun DBD sequence specifically and
was appended to the cFos LZ to produce a peptide, re-
ferred to as A-Fos. Whether the new acidic domain pro-
duces the predicted extended LZ has not been
determined, however it has been shown to produce the
desired effect by increasing binding affinity for cJun
compared to WT cFos. A-Fos was shown to inhibit AP-
1 transactivation in a human hepatoma cell line and has
subsequently been utilised in other cell based assays
where its expression was shown to effectively antagonise
cJun-DNA binding [160]. This acidic extension method-
ology has also been applied by the Vinson group to tar-
get CREB and Myc/Max, and by the Keating group to
target BZLF1 [161–163].
Targeting the full length of the bZIP domain of cJun is
therefore a promising avenue of research to produce
powerful functional antagonists which overcome some
issues with targeting only the DBD or LZ individually.
The potential selectivity issue of targeting the DBD
returns here as an antagonist which binds to the DBD of
cJun will have at least some relevant degree of affinity
for the other AP-1 proteins due to the high sequence
homology of their DBDs. This should not prohibit this
type of cJun antagonist but must be thoroughly consid-
ered nonetheless.
General Challenges in Antagonising cJun
Despite this range of research, no inhibitor of any AP-1
family member has been approved for clinical use for
any disease. Clearly there are some hurdles which must
still be overcome. Firstly, we have discussed evidence of
both apoptotic or anti-apoptotic activity of cJun depend-
ing on cell type [68], and the cJun-dependent upregula-
tion of apoptotic genes such as BIM [96]. These
examples highlight that whilst cJun is generally onco-
genic, that is not always the case. This may mean that
particular tumours are not suited to treatment through
cJun antagonism, or that due to the shifting genetic het-
erogeneity of tumours cJun is only partially effective or
loses efficacy over time, but these are common pitfalls of
cancer treatments and are therefore not prohibitive to
clinical use.
One issue we have not yet raised is the potential for
side effects caused by the role of cJun in healthy tissues
for the vital response to cellular signals. It may be that
antagonism of cJun, which is vital to the functioning of
normal processes, may do more harm than the potential
cancer therapy it provides. Some studies have noted that
cJun can be unobservable in normal tissue but highly
overexpressed in tumour tissue [14, 18], which raises the
possibility of selectively targeting cancerous cells by cJun
antagonism. It may also be possible to modulate the
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target binding affinity to reach an equilibrium value
where an appropriate level of cJun remains unbound.
Some degree of encouragement may also be gleaned
from the development of Omomyc to target c-Myc, an-
other oncogenic TF [164, 165]. This miniprotein func-
tions, at least in part, by directly antagonising c-Myc-
DNA binding. It has shown its therapeutic potential in a
range of cancer models. Omomyc and variants are ex-
pected to enter clinical trials in 2021 [166, 167].
Whether targeting an essential TF will provide more
benefit than side effects is still an open question but in
order to test it we must first develop the cJun-specific
antagonist tools.
Whilst the use of peptide therapeutics is expanding,
there are still significant challenges required to over-
come their known issues such as high production cost,
bioavailability, biostability and immunogenicity. This
may be particularly exacerbated with the larger peptides
required to antagonise the full bZIP domain of cJun. A
range of methodologies to alleviate the potential short-
comings of peptide therapeutics have been developed in-
cluding systematic downsizing [168, 169], chemical mod-
ifications such as acetylation [170–172], incorporation of
non-natural amino acids [173, 174], or cyclisation of the
peptide using linkages such as lactam bridges [175–180].
It will also be important to consider that cJun localises
to the nucleus [181], so peptides may need additional
optimisation to promote cellular and nuclear uptake.
This can often be achieved by the incorporation of cell
penetrating peptides such as penetratin [182], and nu-
clear localisation signals [183]. Any peptide antagonist
will likely require some combination of these modifica-
tions to allow development into a successful clinical
therapeutic.
Conclusion
AP-1 serves as a transcriptional super controller, trans-
activating target genes to modulate a variety of cell sig-
nalling pathways. These signals, from an array of
sources, alter transcription to control processes such as
differentiation, migration, proliferation and apoptosis. As
such, oncogenic alteration of these pathways is also co-
ordinated through AP-1 to produce cancer phenotypes
through the promotion of growth signal autonomy,
angiogenesis, lack of apoptosis and uncontrolled cell mi-
gration. A focus on cJun has highlighted the specific evi-
dence of the role of this AP-1 family member in various
cancers. The study of small molecules and peptides have
both led to progress in the search for antagonists of this
oncogenic cJun activity and provided important research
tools to probe and further validate the role of cJun in
cancer. There have been developments in a variety of
surface targets, whether this is the TRE site of DNA or
some stretch of the bZIP domain, though none have
reached clinical use. This has particularly highlighted the
importance of utilising the sequence diversity of the cJun
LZ to specifically antagonise cJun oncogenic effect, to
avoid antagonism of the potentially anti-oncogenic effect
of other AP-1 family members. Functional antagonism,
rather than non-functional cJun binding, may be best
achieved by an antagonist which binds to the full bZIP
domain to prevent both dimerisation and DNA binding
simultaneously. With a range of challenges still to be
overcome, any method to antagonise cJun-DNA binding
may yet prove to be the route to a clinical therapeutic.
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